Irbesartan

From Wikipedia, the free encyclopedia

(Redirected from Avapro)
Jump to: navigation, search
Irbesartan
Systematic (IUPAC) name
2-butyl-
3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-
1,3-diazaspiro[4.4]non-1-en-4-one
Identifiers
CAS number 138402-11-6
ATC code C09CA04
PubChem 3749
DrugBank APRD00413
Chemical data
Formula C25H28N6O 
Mol. mass 428.53
Pharmacokinetic data
Bioavailability 60–80%
Metabolism Hepatic (CYP2C9)
Half life 11–15 hours
Excretion Renal 20%, faecal 65%
Therapeutic considerations
Licence data

EU US
Pregnancy cat.

D (Au)
Legal status

S4 (Au), POM (UK), ℞-only (U.S.)
Routes Oral

Irbesartan (INN) (pronounced /ɜrbəˈsɑrtən/) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Contents

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).[2]

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.

  1. ^ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.". N Engl J Med 345 (12): 851-60. PMID 11565517. 
  2. ^ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3

v • d • e
Agents acting on the renin-angiotensin system (C09)
ACE inhibitors Benazepril • Captopril • Enalapril • Fosinopril • Lisinopril • Perindopril • Quinapril • Ramipril • Spirapril • Trandolapril
Angiotensin II receptor antagonists (AIIRA) Candesartan • Eprosartan • Irbesartan • Losartan • Olmesartan • Tasosartan • Telmisartan • Valsartan
Renin inhibitors Aliskiren • Remikiren
Retrieved from "http://en.wikipedia.org/wiki/Irbesartan"
Advanced Search
Included Web Search Engines


Safe Search

close

Top Matching Results

Occasionally Search.com will highlight specialized results that are based on the context of your query. Examples of specialized results include specific links to news, images, or video.

Top Matching Results may highlight information from other Search.com pages, content from the CNET Network of sites, or third party content. The listings are based purely on relevance. Search.com does not receive payment for listings in this section but our partners that provide this data may get paid for listing these products.

Sponsored Links

This section contains paid listings which have been purchased by companies that want to have their sites appear for specific search terms and related content. These listings are administered, sorted and maintained by a third party and are not endorsed by Search.com.

Search Results

Search.com sends your search query to several search engines at one time and integrates the results into one list which has been sorted by relevance using Search.com's proprietary algorithm. You can customize the list of search engines included in your metasearch from the preferences.

The search engines that are used in your metasearch may allow companies to pay to have their Web sites included within the results. To view the Paid Inclusion policy for a specific search engine, please visit their Web site. Search.com does not accept payment or share revenue with any search engine partner for listings in this section.